Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
79.36
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 6, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
333
Open
79.36
Bid (Size)
78.95 (1)
Ask (Size)
79.50 (1)
Prev. Close
79.36
Today's Range
79.36 - 79.36
52wk Range
72.87 - 89.74
Shares Outstanding
1,253,809,440
Dividend Yield
3.78%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy
Today 5:15 EST
These three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases.
Via
InvestorPlace
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $11,000 Today
December 06, 2023
Via
Benzinga
Performance
YTD
-7.06%
-7.06%
1 Month
-2.19%
-2.19%
3 Month
+6.90%
+6.90%
6 Month
+0.46%
+0.46%
1 Year
-9.78%
-9.78%
More News
Read More
3 Biotech Stocks That Could Be Multibaggers in the Making
November 30, 2023
Via
InvestorPlace
Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023
November 30, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
2 Biotech Stocks You Can Buy and Hold for the Next Decade
November 30, 2023
Via
The Motley Fool
Looking Into Gilead Sciences's Recent Short Interest
November 22, 2023
Via
Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $1,000 Today
November 21, 2023
Via
Benzinga
Is NASDAQ:GILD suited for dividend investing?
November 20, 2023
Via
Chartmill
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies
November 29, 2023
Via
Benzinga
Exposures
Product Safety
J&J, Gilead, BMS: A look at undervalued dividend payers
November 29, 2023
Via
MarketBeat
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
November 26, 2023
Via
The Motley Fool
Stocks Stall On November 21, 2023, As Systematic Flows Abate
November 21, 2023
Via
Talk Markets
FDA Approves AstraZeneca's Truqap/Faslodex Combo Therapy For Breast Cancer, Competes With Gilead's Drug
November 17, 2023
Via
Benzinga
Exposures
Product Safety
Gilead Sciences's Options: A Look at What the Big Money is Thinking
November 15, 2023
Via
Benzinga
A Closer Look at Gilead Sciences's Options Market Dynamics
November 09, 2023
Via
Benzinga
Where Gilead Sciences Stands With Analysts
November 09, 2023
Via
Benzinga
In a market where value is scarce, NASDAQ:GILD offers a refreshing opportunity with its solid fundamentals.
November 17, 2023
Via
Chartmill
Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead
November 15, 2023
Via
Investor's Business Daily
Kite and Arcellx Announce Expansion in Strategic Partnership
November 15, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review
November 10, 2023
Via
Investor's Business Daily
Global Anal Cancer Market Size Expected to Reach $1.24 Billion In 2028 as Treatments Advance
November 09, 2023
Via
FinancialNewsMedia
Buying the dip in high-yield Gilead Sciences
November 09, 2023
Via
MarketBeat
Exposures
COVID-19
Gilead Sciences to Present at Upcoming Investor Conferences
November 08, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Tops Q3 Earnings And Revenue Estimates
November 07, 2023
Via
Talk Markets
Gilead Sciences (GILD) Q3 2023 Earnings Call Transcript
November 07, 2023
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.